Business concept and strategy
Q-linea’s business concept is to develop and supply healthcare solutions that enable diagnosis and treatment of infectious diseases in the shortest possible time
- Regulatory strategy: Carry out necessary activities for upholding regulatory compliance and market access of the ASTar instrument and consumables in the US and other key geographies. The first product focuses on sepsis diagnostics;
- Commercial strategy: The company addresses key markets directly through local subsidiaries and simultaneously work with distributors to achieve broader and faster market penetration. Initially, the focus will be on key geographies in Europe and the US market. Sales will consist of instruments and consumables, with the latter expected to generate most of the potential revenue. In collaboration with distributors, the distributor will handle all first-hand service and Q-linea will be responsible for expert knowledge on more difficult service questions. Q-linea will continue to explore business opportunities for Podler
- Health economic strategy: The Company will continue to focus on the clinical and economic benefits for a hospital to implement rapid AST by carrying out health-economic studies and smaller studies that focus on showing clinical benefit. The purpose of these is to use the study results as sales support.
- Operational strategy: continued Cuilding of Q-linea’s infrastructure to secure development and production capacity;
- Product development strategy: Continued development of the ASTar offering and new applications and products;
- Intellectual property strategy: Continued development and maintenance of a broad and relevant IP portfolio; and
- Service & Support strategy: Continue to build a standalone service organization with a focus on expert service and continue to develop the company’s application specialists to attend and follow up customer visits